A plain language summary of the 5-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma

被引：7

作者：

Dummer, Reinhard ^{[1
]}

Flaherty, Keith T. ^{[2
]}

Robert, Caroline ^{[3
]}

Arance, Ana ^{[4
,5
]}

de Groot, Jan Willem B. ^{[6
]}

Garbe, Claus ^{[7
]}

Gogas, Helen J. ^{[8
]}

Gutzmer, Ralf ^{[9
,10
]}

Krajsova, Ivana ^{[11
]}

Liszkay, Gabriella ^{[12
]}

Loquai, Carmen ^{[13
]}

Mandala, Mario ^{[14
]}

Schadendorf, Dirk ^{[15
,16
]}

Yamazaki, Naoya ^{[17
]}

di Pietro, Alessandra ^{[18
]}

Cantey-Kiser, Jean ^{[19
]}

Edwards, Michelle ^{[20
]}

Ascierto, Paolo A. ^{[21
]}

机构：

[1] Univ Hosp Zurich, Zurich, Switzerland

[2] Massachusetts Gen Hosp, Boston, MA USA

[3] Gustave Roussy & Paris Saclay Univ, Villejuif, France

[4] Hosp Clin Barcelona, Barcelona, Spain

[5] IDIBAPS, Barcelona, Spain

[6] Isala Oncol Ctr, Zwolle, Netherlands

[7] Univ Hosp Tubingen, Tubingen, Germany

[8] Natl & Kapodistrian Univ Athens, Athens, Greece

[9] Hannover Med Sch, Hannover, Germany

[10] Ruhr Univ Bochum, Minden Campus, Bochum, Germany

[11] Univ Hosp Prague, Prague, Czech Republic

[12] Natl Inst Oncol, Budapest, Hungary

[13] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Mainz, Germany

[14] Univ Perugia, Perugia, Italy

[15] Univ Hosp Essen, West German Canc Ctr, Essen, Germany

[16] German Canc Consortium, Partner Site Essen, Essen, Germany

[17] Natl Canc Ctr, Tokyo, Japan

[18] Pfizer, Milan, Italy

[19] PharPoint Res, Durham, NC USA

[20] Pfizer, New York, NY USA

[21] Ist Nazl Tumori IRCCS Fdn Pascale, Naples, Italy

来源：

FUTURE ONCOLOGY | 2023年 / 19卷 / 16期

关键词：

binimetinib; BRAF inhibitor; BRAF V600; COLUMBUS; COLUMBUS part 1; encorafenib; MEK inhibitor; melanoma; plain language summary; vemurafenib;

D O I：

10.2217/fon-2022-1258

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1091 / 1098

页数：8